...
首页> 外文期刊>Cellular Physiology and Biochemistry >Circulating Long Noncoding RNAs as Biomarkers for Predicting Head and Neck Squamous Cell Carcinoma
【24h】

Circulating Long Noncoding RNAs as Biomarkers for Predicting Head and Neck Squamous Cell Carcinoma

机译:循环长非编码RNAs作为预测头颈部鳞状细胞癌的生物标志物

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background/Aims The anatomical complexity of the head and neck region and the lack of sufficiently specific and sensitive biomarkers often lead to the diagnosis of head and neck squamous cell carcinoma (HNSCC) at advanced stages. To identify novel biomarkers for early diagnosis of primary HNSCC through a minimally invasive method, we investigated circulating long noncoding RNA (lncRNA) levels in plasma of HNSCC patients. Methods The global lncRNA expression profiles of HNSCC patients were measured using microarray and next-generation RNA-sequencing (RNA-seq) data from both circulating and tissue samples. The diagnosis prediction model based on the lncRNA signatures and clinical features was evaluated by multi-stage validation and risk score analysis. Results The data showed that 432 lncRNA transcripts were differentially expressed by fold changes of > 4 in circulating samples and 333 in tissues samples, respectively. Only 12 lncRNAs consistently emerged in these two kinds of samples. After the risk score analysis including a multistage validation, we identified three lncRNAs, namely, HOXA11-AS, LINC00964 and MALAT1, which were up-regulated in the plasma of HNSCC patients compared with those in healthy controls with merged areas under the curve (AUCs) in training and validation sets of 0.925 and 0.839, respectively. Conclusion HOXA11-AS, LINC00964 and MALAT1 might be potential circulating biomarkers for the early detection of HNSCC in the future.
机译:背景/目的头颈部区域的解剖学复杂性以及缺乏足够特异性和灵敏的生物标记物通常会导致晚期头颈鳞状细胞癌(HNSCC)的诊断。为了确定通过微创方法早期诊断原发性HNSCC的新生物标志物,我们研究了HNSCC患者血浆中循环的长非编码RNA(lncRNA)水平。方法使用循环和组织样本中的微阵列和下一代RNA测序(RNA-seq)数据,测量HNSCC患者的整体lncRNA表达谱。通过多阶段验证和风险评分分析,评估了基于lncRNA特征和临床特征的诊断预测模型。结果数据显示432个lncRNA转录本通过>的倍数变化而差异表达。循环样本中的4个和组织样本中的333个。在这两种样品中仅持续出现12个lncRNA。经过包括多阶段验证的风险评分分析后,我们确定了3种lncRNA,即HOXA11-AS,LINC00964和MALAT1,与健康人的曲线下融合区域(AUC)相比,HNSCC患者血浆中的lncRNA上调)分别设置为0.925和0.839。结论HOXA11-AS,LINC00964和MALAT1可能是将来早期检测HNSCC的潜在循环生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号